At IBDENC, we believe in engage, educate and empower. Our IBD Journal Scan is one way we deliver on that promise: by curating key articles from high-impact journals every month, we offer a clear, expert-driven snapshot of what’s new and noteworthy in IBD research. Whether you're a clinician, researcher, or educator, this resource helps you stay on the frontline of cutting-edge science, with older scans archived so you can revisit past insights as well.
IBD Journal Scan
Key articles from high impact journals in last month
AUG-2026
This month's featured research explores key advances shaping the future of inflammatory bowel disease (IBD) care, including global projections of the rising IBD burden through 2045, reassuring long-term cardiovascular safety of biologics and oral small molecules, sustained three-year efficacy of mirikizumab in ulcerative colitis, the emerging role of AI-powered endo-histo-omics in precision medicine, and new insights into how sulfur-metabolizing gut microbes may drive persistent symptoms in quiescent Crohn's disease. Together, these studies highlight advances in epidemiology, therapeutic safety, long-term disease management, artificial intelligence, and microbiome science, reinforcing the shift toward more personalized, data-driven approaches to improving outcomes for patients with IBD.
Global IBD Burden Set to Rise Sharply by 2045
Inflammatory bowel disease (IBD) continues to expand as a global health challenge, following four epidemiologic stages: emergence, accelerated incidence, compounding prevalence, and prevalence equilibrium. In many early industrialized countries, IBD prevalence is expected to exceed 1% of the population within the next decade before stabilizing. Using advanced disease modelling, researchers project prevalence trends through 2045, providing valuable insights for future healthcare planning. At the same time, newly industrialized nations are expected to transition into the compounding prevalence stage, with rapidly increasing numbers of patients. These projections emphasize the urgent need for prevention strategies, improved healthcare infrastructure, and long-term policies to meet the growing global burden of IBD over the next two decades.
Biologics and Small Molecules Show Reassuring Cardiovascular Safety in IBD
A large real-world study found that biologics and oral small molecules (OSMs) are not associated with an increased risk of major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD). Using data from a multi-institutional database, researchers observed that biologic-treated patients had lower risks of myocardial infarction, stroke, and all-cause mortality over one and three years, with no increase in VTE. Similarly, OSM therapy did not increase the risk of cardiovascular events or VTE, including in older patients with cardiovascular risk factors, while showing reduced all-cause mortality. These findings reinforce the favorable long-term safety profile of advanced IBD therapies in routine clinical practice.
Mirikizumab Demonstrates Sustained Three-Year Benefits in Ulcerative Colitis
Results from the LUCENT-3 open-label extension study show that mirikizumab provides durable efficacy and a favorable safety profile through 152 weeks (3 years) in patients with moderately-to-severely active ulcerative colitis. Most patients who responded or achieved remission at one year maintained clinical response, corticosteroid-free remission, endoscopic healing, and histologic-endoscopic mucosal remission through year three. Improvements in bowel urgency, rectal bleeding, stool frequency, and abdominal pain were also sustained over time. Safety outcomes remained consistent, with low rates of serious adverse events, opportunistic infections, and treatment discontinuation. These long-term findings support mirikizumab as an effective maintenance therapy capable of delivering sustained disease control and improved quality of life in ulcerative colitis.
AI-Powered ‘Endo-Histo-Omics’ Advances Precision Care in IBD
Artificial intelligence is transforming inflammatory bowel disease (IBD) care through the emerging ‘endo-histo-omics’ approach, which integrates clinical, endoscopic, histological, and molecular data into a unified framework. By combining multiple layers of patient information, this AI-enabled strategy improves disease characterization, predicts clinical outcomes, and supports more precise patient stratification. It also enhances the assessment of intestinal barrier integrity, helping clinicians identify patients who may benefit from targeted therapeutic interventions. As precision medicine continues to evolve, endo-histo-omics represents a promising step toward personalized IBD management, enabling data-driven treatment decisions and potentially improving long-term disease outcomes.
Gut Sulfur Metabolism May Explain Persistent Symptoms in Quiescent Crohn’s Disease
A multi-omics study suggests that altered sulfur metabolism and sulfidogenic gut microbes may contribute to persistent gastrointestinal symptoms in patients with quiescent Crohn’s disease, even when inflammation is well controlled. Researchers identified enrichment of sulfur-related metabolic pathways, including cysteine and methionine metabolism, along with dysregulated bacterial sulfur metabolism genes in symptomatic patients. These microbial and metabolic changes were also linked to pathways associated with mitochondrial dysfunction, offering new insights into symptom persistence beyond active inflammation. The findings highlight the potential of microbiome and metabolomic profiling to identify biomarkers and therapeutic targets, paving the way for more personalized approaches to managing ongoing symptoms in Crohn’s disease.